Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel With or Without Carboplatin in mCRPC
NCT01505868Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2012
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carboplatin in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dosage at 6 months and Progression Free Survival up to 5 years. Started Jul 2012; status: completed.
02
Drugs
carboplatin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01505868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01505868.